Pulmonx (NASDAQ:LUNG) is gearing up to announce its quarterly earnings on Wednesday, 2026-03-04. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Pulmonx will report an earnings per share (EPS) of $-0.39.

Investors in Pulmonx are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Past Earnings Performance

The company's EPS beat by $0.07 in the last quarter, leading to a 18.88% drop in the share price on the following day.

Here's a look at Pulmonx's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.41	-0.40	-0.40	-0.45
EPS Actual	-0.34	-0.38	-0.36	-0.33
Price Change %	-18.88	-41.59	-21.95	32.23

Market Performance of Pulmonx's Stock

Shares of Pulmonx were trading at $1.525 as of March 02. Over the last 52-week period, shares are down 81.32%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Get to Know Pulmonx Better

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Pulmonx's Financial Performance

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Positive Revenue Trend: Examining Pulmonx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.47% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Pulmonx's net margin is impressive, surpassing industry averages. With a net margin of -64.91%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Pulmonx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -21.62% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -9.78%, the company showcases effective utilization of assets.

Debt Management: Pulmonx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.94.

To track all earnings releases for Pulmonx visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.